This HTML5 document contains 191 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
phttp://www.wikidata.org/prop/
wikibasehttp://wikiba.se/ontology#
n9http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34593276
rdf:type
wikibase:Item
schema:description
мақолаи илмӣ 2008年论文 vetenskaplig artikel 2008年论文 2008 թվականի հունիսին հրատարակված գիտական հոդված artigo científico (publicado na 2008) artículo científico publicado en 2008 2008年論文 επιστημονικό άρθρο ২০০৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ научна статия wetenschappelijk artikel 2008年論文 article scientific مقالهٔ علمی bài báo khoa học articolo scientifico artículu científicu espublizáu en 2008 artikulong pang-agham articol științific 2008年论文 2008年論文 სამეცნიერო სტატია 2008年论文 2008 թուականի Յունիսին հրատարակուած գիտական յօդուած videnskabelig artikel (udgivet 2008) научни чланак scientific article 2008年论文 bilimsel makale wissenschaftlicher Artikel artykuł naukowy мақолаи илмӣ מאמר מדעי سائنسی مضمون scienca artikolo научная статья artigo científico vedecký článok 2008年論文 vitskapeleg artikkel مقالة علمية artigo científico (publicado na 2008) article scientifique (publié 2008) 2008年の論文 article científic tieteellinen artikkeli наукова стаття, опублікована в червні 2008 научни чланак 2008年論文 vitenskapelig artikkel mokslinis straipsnis teaduslik artikkel 2008년 논문 tudományos cikk 2008 nî lūn-bûn บทความทางวิทยาศาสตร์ vědecký článek artikull shkencor 2008年论文 naučni članak
p:P577
wds:Q34593276-4B6F5B57-8511-4557-B75C-82499F18363D
wdt:P577
2008-06-16T00:00:00Z
p:P407
wds:Q34593276-DC081383-484D-4F21-B823-F2CF7BDAB8EC
wdt:P407
wd:Q1860
p:P2860
wds:Q34593276-348BEA45-1237-490B-8A40-1C2BAAEB045E wds:Q34593276-1DFA9E60-588D-4A16-AA7F-E99042502CD7 wds:Q34593276-17B76043-1C3B-43E3-AA58-0C5B9DBC2E43 wds:Q34593276-183A26CA-6730-43EE-BB6B-DAAAD608D938 wds:Q34593276-1BDEDB16-94FC-4869-A4CB-6AADB5A09CE0 wds:Q34593276-0BACEBE9-139E-4FA9-A82C-ADBB9CD8F241 wds:Q34593276-0E4ED79D-12AA-4792-86F0-B182FFC25049 wds:Q34593276-836E8203-FEF7-4E39-9B09-876604D390DA wds:Q34593276-8C499075-34B1-4818-81E5-0FFB30E3C66B wds:Q34593276-8E7672B7-5503-4A71-9357-436A0DD2F06C wds:Q34593276-7BED458A-65C9-41D4-AC97-8CFBBA2524F9 wds:Q34593276-7D131DAA-0467-41A7-A27D-C964D82BD2FD wds:Q34593276-568843BB-AB98-41CA-BBE1-28F95637088D wds:Q34593276-5FBDA256-0354-4911-B1D3-4D1A2436D118 wds:Q34593276-61EBC7E0-6C3C-49A3-9B83-545132582A96 wds:Q34593276-4B6FB214-326F-4B45-8FE9-416ABBDECA5E wds:Q34593276-4DF31067-AAF5-436B-8AD5-DDA6A43D8C20 wds:Q34593276-CA760FA6-BEB8-4DCB-B62B-BBD1F606AC6C wds:Q34593276-CE2D4348-8FC3-4A1F-A66F-57E7E796EDAA wds:Q34593276-A99A401A-3A8B-4997-9DB1-3B7EE740FE2C wds:Q34593276-AC508E4F-15E2-4960-928E-C035CD52DCDE wds:Q34593276-AC60C632-BFFD-4FE0-AE1E-07D4D0EDFDDD wds:Q34593276-B06B5674-6624-4AB5-8C87-3A0371E5AAD0 wds:Q34593276-A08FFE7D-1D4A-4F2D-BFA2-0BA511E27008 wds:Q34593276-A6AA7A83-2E87-4536-8088-9D98C37D2AA9 wds:Q34593276-9C673426-3E92-45C3-886A-57E35B9BD726 wds:Q34593276-9D84FA9F-A240-447E-92B5-BE0422CFFC32 wds:Q34593276-ECC057F4-8724-48FE-AD9F-20767140FBA3 wds:Q34593276-F5BB76F2-DB7A-4EE1-85DC-F10820B4391A wds:Q34593276-DA495CA3-DDDD-4E17-A00B-B5BD30D87E76 wds:Q34593276-DE7DC5DE-B1A6-41CF-9F03-D365912033D1 wds:Q34593276-CF9A8320-56FA-488E-AF1F-65226A77BE8E wds:Q34593276-CF9CBC16-DD51-4AA8-A270-C54E4E8E7159 wds:Q34593276-D3172DFC-9B13-4956-9D5C-1137502160C5
wdt:P2860
wd:Q54104366 wd:Q73218719 wd:Q44408358 wd:Q46468974 wd:Q54008419 wd:Q77363619 wd:Q39715719 wd:Q69551029 wd:Q44240281 wd:Q44799859 wd:Q80974691 wd:Q73336677 wd:Q52379837 wd:Q28247684 wd:Q40346094 wd:Q34493792 wd:Q38485418 wd:Q50955175 wd:Q34753320 wd:Q29617915 wd:Q34553536 wd:Q41562033 wd:Q33333711 wd:Q27824859 wd:Q27824840 wd:Q44799721 wd:Q71767600 wd:Q28201363 wd:Q29547769 wd:Q70330912 wd:Q73825094 wd:Q53599858 wd:Q43905996 wd:Q72736472
p:P2093
wds:Q34593276-F08B6692-E495-4695-A969-E4D1552A1A00 wds:Q34593276-E2DAD367-540A-4EE6-AC08-27C2EDFA8C79 wds:Q34593276-2CEA2683-A8C8-469D-98CA-78CED463E179
wdt:P2093
Edison T Liu Robert J Mayer Andreas Neubauer
rdfs:label
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study
skos:prefLabel
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study
schema:name
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study
p:P50
wds:Q34593276-79C05894-6137-4E19-85C7-95F69E8AC9D3 wds:Q34593276-84CFB499-AABE-4B25-A225-66694EFD94D0 wds:Q34593276-02C22E2A-CA6E-4EC1-9EB3-EB4BCE817DE5 wds:Q34593276-D64BCD42-D110-43A4-8D13-3B4B5F35B7A5 wds:Q34593276-DA116BAF-4FED-4132-8A98-E5EA75AFA1A0 wds:Q34593276-932C9C8C-921F-4F27-9652-6F63E67A8449 wds:Q34593276-A3DBB2AF-00EA-49C2-A010-51B3B543D010
wdt:P50
wd:Q42323747 wd:Q41899936 wd:Q114413073 wd:Q66411928 wd:Q66385542 wd:Q66370794 wd:Q4793409
p:P1476
wds:Q34593276-6F62C937-B9DD-4032-8BFF-A9C7E1752B15
wdt:P1476
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study
p:P304
wds:Q34593276-C6FC26B7-8423-49E8-9B2B-2D7D89CE4997
wdt:P304
4603-4609
p:P31
wds:Q34593276-1E8CD3CC-34D1-4876-82B2-A4824FC1BF27
wdt:P31
wd:Q13442814
p:P921
wds:Q34593276-A90D0AAE-D3D8-46B2-88AB-F740F9C5E162 wds:Q34593276-1AE9A4DA-F861-465E-953C-6D03F904450A wds:Q34593276-23ED9DC6-CD6B-4A55-BCBB-BB0285A7C107 wds:Q34593276-2A9B3D7C-5255-4579-939B-5CE00FBF9F8F
wdt:P921
wd:Q264118 wd:Q29496 wd:Q180983 wd:Q181600
p:P698
wds:Q34593276-7479EB06-77B0-4BF2-852E-FEBEA1DECFBA
wdtn:P698
n11:18559876
wdt:P698
18559876
p:P1433
wds:Q34593276-2D3FF983-6F4C-43B2-BAC7-C30305987D39
wdt:P1433
wd:Q400292
p:P433
wds:Q34593276-3D4FB5A9-17AA-4E70-911D-EEBF3C92C128
p:P478
wds:Q34593276-C5D263D6-D82D-4C99-AED3-8D1BA4B7C79A
wdt:P433
28
wdt:P478
26
p:P356
wds:Q34593276-91201C1B-742E-40FB-9BA4-2F39F800B1EC
wdtn:P356
n9:JCO.2007.14.0418
wdt:P356
10.1200/JCO.2007.14.0418
p:P932
wds:Q34593276-22886DC0-A39F-458D-B84E-6B874219286C
wdt:P932
2653132